|

Hyperpolarized 13C-Pyruvate Clinical Trials

9 actively recruiting trials across 3 locations

▼ -1 trial since June 2026

Also known as: (13C) pyruvate, HP 13C, HP [1-13C]pyruvate, HP-13C, Hyperpolarized (HP) carbon^13 (13C)-pyruvate +2 more

Pipeline

Early 1: 1Phase 1: 2Phase 2: 2Phase 1/2: 2

Top Sponsors

  • University of Maryland, Baltimore2
  • University of California, San Francisco2
  • University of Texas Southwestern Medical Center1
  • Sunnybrook Health Sciences Centre1
  • Robert Bok, MD, PhD1

Indications

San Francisco, California4 trials

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

University of California, San Francisco

Phase 1/2
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

University of California, San Francisco

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco

Phase 2
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

University of California, San Francisco

Early 1

Other2 trials

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body
Phase 2
Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)
Phase 1

Baltimore, Maryland2 trials

HP Pyruvate MRI in Cancers

University of Maryland Medical Center

Phase 1/2
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Rosy Njonkou Tchoquessi

Phase 1

Dallas, Texas1 trial

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

UT Southwestern Medical Center

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.